Supplementary Figure S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)

Answers are grounded in this paper and cite their sources.

• What was the primary endpoint, and how big was the effect?
• What are the main limitations?
• How does this compare with earlier trials?